CHR. OLESEN PHARMACEUTICALS A/S — Credit Rating and Financial Key Figures
CVR number: 32090168
Jægersborg Alle 164, 2820 Gentofte
Income statement (kEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 1 026.37 | 740.31 | 1 215.29 | 1 382.57 | 915.97 |
| Employee benefit expenses | - 307.34 | - 294.29 | - 474.81 | - 531.19 | - 538.50 |
| Total depreciation | -40.00 | -40.02 | |||
| EBIT | 679.04 | 406.00 | 740.48 | 851.38 | 377.47 |
| Other financial income | 82.07 | 67.19 | 114.88 | 379.09 | 374.78 |
| Other financial expenses | - 176.77 | - 151.13 | - 257.99 | - 688.77 | - 648.72 |
| Pre-tax profit | 584.34 | 322.06 | 597.37 | 541.69 | 103.53 |
| Income taxes | - 129.57 | -70.95 | - 132.13 | - 120.50 | -32.97 |
| Net earnings | 454.76 | 251.10 | 465.24 | 421.19 | 70.56 |
Assets (kEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 40.02 | ||||
| Tangible assets total | 40.02 | ||||
| Investments total | |||||
| Long term receivables total | |||||
| Finished products/goods | 3 156.88 | 4 368.41 | 4 546.43 | 3 634.49 | 2 373.50 |
| Inventories total | 3 156.88 | 4 368.41 | 4 546.43 | 3 634.49 | 2 373.50 |
| Current trade debtors | 2 296.56 | 2 465.14 | 2 575.46 | 3 768.48 | 2 909.67 |
| Current amounts owed by group member comp. | 3 890.49 | 6 088.35 | 7 759.58 | 6 351.62 | 5 278.91 |
| Prepayments and accrued income | 0.18 | 2.62 | 26.63 | 33.56 | |
| Current other receivables | 25.77 | 24.22 | 91.33 | 34.47 | |
| Current deferred tax assets | 3.77 | 9.45 | 9.45 | 9.45 | |
| Short term receivables total | 6 216.59 | 8 587.35 | 10 347.11 | 10 247.51 | 8 256.61 |
| Cash and bank deposits | 0.06 | 2.35 | 92.43 | 182.95 | 206.05 |
| Cash and cash equivalents | 0.06 | 2.35 | 92.43 | 182.95 | 206.05 |
| Balance sheet total (assets) | 9 413.55 | 12 958.11 | 14 985.98 | 14 064.96 | 10 836.16 |
Equity and liabilities (kEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Share capital | 79.17 | 79.17 | 79.17 | 79.17 | 79.17 |
| Shares repurchased | 300.00 | ||||
| Other reserves | - 200.00 | ||||
| Retained earnings | 65.24 | 520.00 | 771.10 | 1 236.34 | 1 357.53 |
| Profit of the financial year | 454.76 | 251.10 | 465.24 | 421.19 | 70.56 |
| Shareholders equity total | 599.17 | 850.27 | 1 315.51 | 1 736.70 | 1 607.26 |
| Non-current liabilities total | |||||
| Current loans from credit institutions | 7 098.83 | 10 217.41 | 10 843.99 | 10 864.75 | 3 911.18 |
| Current trade creditors | 1 120.37 | 775.01 | 1 621.55 | 568.96 | 848.40 |
| Current owed to group member | 285.76 | 881.64 | 771.03 | 570.62 | 4 161.73 |
| Short-term deferred tax liabilities | 275.60 | 211.03 | 343.15 | 252.08 | 275.63 |
| Other non-interest bearing current liabilities | 33.83 | 22.75 | 90.75 | 71.84 | 31.96 |
| Current liabilities total | 8 814.38 | 12 107.84 | 13 670.47 | 12 328.25 | 9 228.90 |
| Balance sheet total (liabilities) | 9 413.55 | 12 958.11 | 14 985.98 | 14 064.96 | 10 836.16 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.